Bristol-Myers Squibb is paying Zymogenetics $85M UF in cash, part of a $1.12B deal for the rights to develop its PEG-Interferon lambda (in Phase 1) for treating hepatitis C. ZymoGenetics will get $430M if it reaches certain development milestones and approval of PEG-Interferon lambda , $287M for development and regulatory approvals of drugs to treat other conditions (usually out in there to cover asses and sweeten the deal), and $285M for meeting certain sales goals. Sweet. ZymoGenetics already sells Recothrom, a genetically engineered topical thrombin to stop bleeding. Yahoo! Finance

Singulex closed a $19M financing round, led by JAFCO Co., Ltd. and supported by existing investors: OrbiMed Advisors and Fisk Ventures. The $19M will be used for the commercialization of Singulex’s technologies in the diagnostics/biomarker market. Singulex uses something called “Erenna” technology and immunoassays to help them better understand the effects of compounds early in development. The technology also allows for the detection and measurement of minute protein biomarker changes at very low levels, facilitating development of personalized medicines. We’ll be covering Singulex in greater detail in an upcoming company profile. FierceBiotech

BiPar Sciences announced a $20M raise from existing equity investors Domain Associates, Canaan Partners, Vulcan Capital, PolyTechnos Venture-Partners, Asset Management Company and Quantum Technology Partners, along with venture-debt lender Lighthouse Capital Partners. BiPar is trying to advance BSI-201, their PARP inhibitor for metastatic triple negative breast cancer (TNBC), to Phase 3 registration studies. BiPar is also another company we’ll be covering soon. MSNBC

And that’s that…we’re exhausted…good night!

Image from aboutus

Related Posts